graham74GC Profile Banner
Graham Collins Profile
Graham Collins

@graham74GC

Followers
16K
Following
11K
Media
2K
Statuses
9K

Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.

Opinions are mine
Joined December 2013
Don't wanna be here? Send us removal request.
@graham74GC
Graham Collins
@graham74GC
1 day
Kamdar et al; 3y FU of TRANSFORM study - Liso-cel vs standard 2nd line in 1st relapse large B-cell NHL. Impressive PFS & EFS benefit.Trend to OS but not stat significant. 66% crossed over to liso-cel from control arm. No new tox signal.
Tweet media one
2
15
42
@graham74GC
Graham Collins
@graham74GC
5 days
What a fascinating thread!.
@whosainastro
Muhammad Hussain, MD
@whosainastro
6 days
1/.Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet? .If you work in pathology or oncology, you’ve likely come across Ki-67 many times. But where does the name come from?. A short 🧵 on the origins, function, and significance of Ki-67.
Tweet media one
2
3
17
@graham74GC
Graham Collins
@graham74GC
8 days
Experts such as @ProfChrisPFox @CwynKate @Jessica_Okosun @wendster @pammckay123 and many, many more!.
0
1
6
@graham74GC
Graham Collins
@graham74GC
9 days
It’s back and it’s online. The fantastic #lymphomaManagement course. With much thanks to @LymphomaAction for their support as always. Do sign up to learn about state of the art management of this fascinating disease from international experts. #lymsm.
@LymphomaAction
LymphomaAction
@LymphomaAction
9 days
#LymphomaManagement is back! We’re proud to deliver our leading course for healthcare professionals virtually in 2025, in collaboration with the Oxford Centre for #Haematology (@OxfordHaem). Book today 👉 [1/3]. #LymSM #Lymphoma @tobyeyre82 @graham74GC
Tweet media one
4
7
25
@graham74GC
Graham Collins
@graham74GC
10 days
RT @tobyeyre82: Zanubrutinib approved for relapsed #MCL by @NICEComms #lymsm .Final draft guidance avaliable.https:….
0
6
0
@graham74GC
Graham Collins
@graham74GC
19 days
Really hope bispecifics will become available for relapsed mantle.
@elizabeth_budde
L. Elizabeth Budde, M.D., Ph.D.
@elizabeth_budde
19 days
ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% .CRS all low grade and resolved.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
2
9
41
@graham74GC
Graham Collins
@graham74GC
19 days
Reinforces that getting patient to ASCT is important. In my view this trumps CAR-T (if chemosensitive of course).
@JhaveriKhushali
Khushali Jhaveri
@JhaveriKhushali
19 days
🧠7y MARIETTA update in SCNSL.PFS 33% in pts <70 (MATRIX/RICE ± ASCT).Best PFS in tx-naïve (52%), isolated CNS relapse (33%), synchronous (11%).Resp after 2cy → better outcomes.Auto-SCT → PFS (64%).IT chemo → better PFS (p=0.017).Trend: single CNS site = better PFS.#ICML2025
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
7
30
@graham74GC
Graham Collins
@graham74GC
20 days
Lotis-7: loncaT with glofit RR DLBCL.Small nos and early data but VERY high response rates with well over 80% CMR rate. One to watch. #18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
2
17
69
@graham74GC
Graham Collins
@graham74GC
20 days
Tessoulin - tafa, Len, ritux in elderly 1L DLBCL.• induction 20mg Len, reduced for consolidation.• ORR 72%.• but 28% discon due to AE so is toxic.#18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
9
3
13
@graham74GC
Graham Collins
@graham74GC
20 days
Wurm-Kuczera: R-pola-glo in unfit 1L DLBCL. Anthacycline ineligible ‘Ix discretion’.• glofit, pola, ritux. Fixed duration .• EOT: 90% ORR & 81% CMR.• 4% ICANs, G3+ CRS 2.5%.V impressive responses. Need to see survival endpoints. #18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
18
40
@graham74GC
Graham Collins
@graham74GC
20 days
Belada - Epcor mono in older / comorbid DLBCL. • over 80 or 75 with CV risk factors (many simply had HT).• ORR 78% CRR 70%.• CR appeared durable.• 6 mo PFS 73%.• 16% ICANs, 71% CRS.Good results but I think many of these could have had anthracycline. #18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
5
0
8
@graham74GC
Graham Collins
@graham74GC
20 days
Thurner et al - Optimal >60 less fav.• liposomal doc had more neuropathy.• PET guided RT to bulk, comparison with Ricover trial showed same results.• whole trial did better than Ricover trial.Supports omission of RT to initial bulk if PET neg. #18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
5
3
9
@graham74GC
Graham Collins
@graham74GC
20 days
Fujimoto et al - Allo / auto in ENKT? Japanese data. • if in CR, ASCT appear superior to allo.• if in PR, allo appears preferable.• no impact on source of allo cells.I normally allo these pts in CR1 so potentially practise changing. #18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
13
37
@graham74GC
Graham Collins
@graham74GC
20 days
Held et al - NIVEAU trial. Nivo-GemOx vs GemOx RR PTCL.• 76 pts part of bigger trial.• PFS no diff but was ⬆️ when MVA performed.• responses ⬆️.• BUT ⬆️ toxic incl ‘infn’ (?hyperinfl state instead); ⬆️ deaths. Doubt there will be further development. #18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
8
2
12
@graham74GC
Graham Collins
@graham74GC
20 days
Patel: JNJ4496 (anti CD19/20 tandem CAR) RR DLBCL, 41BB costim.• global Ph 1B.• med age 72y.• at RP2D, ORR 100%, CRR 80%.• no G3+ CRS, 8% ICANs.Very impressive results .#18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
5
6
15
@graham74GC
Graham Collins
@graham74GC
21 days
Ghesquiere: TIRHOL study of tislelizumab in RR #Hodgkin.• 2 cohorts post ASCT or pre.• ORR just under 70%: CMR approx 30%.• some durable responses .Overall a little disappointing as doesn’t reproduce Chinese study with high CMR rate. #18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
2
3
@graham74GC
Graham Collins
@graham74GC
21 days
Dreyfuss et al.• ISRT & Pembro in localised relapsed cHL.• RT dose varied according to response to Pembro.• generally safe & good outcomes.• did not seem to impair subseq Rx.Consider for older relapsed pts .#18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
4
5
@graham74GC
Graham Collins
@graham74GC
21 days
Davison et al - PRO substudy of S1826 substudy. Interesting outputs:.• NivoAVD showed more fatigued compared with BV-AVD on treatment but did not meet ‘clin significant’ threshold. • BV-AVD showed excess neuropathy which had a clinically meaningful impact. #ICML25 #lymsm
Tweet media one
Tweet media two
Tweet media three
4
2
5
@graham74GC
Graham Collins
@graham74GC
21 days
Evans et al: E-HIPI prognostic score early cHL.• Holistic consortium.• 1 binary factor: female sex better prog.• 3 continuous: max tumour diam, Hb and albumin. Great work from . Online calculator now available! .#18ICML #ICML25 #lyms
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
1
11
@graham74GC
Graham Collins
@graham74GC
21 days
Great work by @ABarrettHaem. NHSE data, older #Hodgkin pts. Outcomes ⬆️ with dox. Clearly may reflect selection, but interesting assocn seen between regional difference in dox use and outcome. Take home message: if safe to use dox then do use it! . #18ICML #ICML25 #lymsm
Tweet media one
Tweet media two
1
4
17